First, good top line results are already priced in. So if they are good look for a nice sell off to the 5 area. If they are bad then you are going to 2 bucks. So lets see.... 1.70 on the downside or 4 dollars on the downside... You decide
Oh really---top line results are priced in---why? I got some top line results on GALN data for BMRN late last year and that stock went up $10.00/share and its an Orphan drug! Not suggesting that kind of rise is warrented here, but your statement is just basically sometimes wrong!
I already decided--bring on the data!
This is a solid long term investment here. TSRX longs are not fools... Dragon knows clinical medicine, reads JAMA and invests plenty of fireballs in good biotechs. NO time for chess playing. MRSA is rising, TSRX will continue to be bullish and TSRX longs will prosper. Hard $8.. end of March.
Sentiment: Strong Buy
I don't thing you're correct. Tsrx has plenty of catalysts pending after the announcement, such as accelerated FDA approval, potential partnership, and a potential buyout. They also have other drugs in the pipeline. As always, do your own DD